Hormone therapy stories

May 31, 2026

Johnson & Johnson's Prostate Cancer Drug Reduces Risk of Cancer Spread and Death in Late-Stage Study

J&J's Erleada used with hormone-blocking therapy six months before and after prostate surgery improved cancer elimination rates and reduced the risk of cancer spread and death in a late-stage trial for prostate cancer patients.

May 31, 2026·2 sources

Apr 9, 2026

HRT Patches Treat Prostate Cancer as Effectively as Standard Injections with Fewer Side Effects

A large UK trial published in the New England Journal of Medicine found that women's hormone replacement therapy patches can treat prostate cancer just as effectively as standard hormone injections but with fewer severe side effects.

Apr 9, 2026·1 source

Top claims

▪The Erleada trial enrolled more than 2,000 patients with high-risk localized or locally advanced prostate cancer who were candidates for prostate gland removal surgery.
▪Erleada, known chemically as apalutamide, belongs to a class of drugs called androgen receptor pathway inhibitors that block signals that drive prostate-cancer growth.
▪No androgen receptor pathway inhibitors are approved for localized high-risk prostate cancer with either surgery or radiation as of May 31, 2026.

Topics

Clinical trials Cancer treatment breakthroughs Health Hormone optimization Biomarkers & bloodwork testing

Related entities

Oncology United Kingdom Women's health

Featured Stories

OpenAI pauses development of Astra AI model over critical cybersecurity capability concerns

Aug 7, 2026·2 sources